Drugs / LV-w1.6 WASp
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01347242 | Mar 2011 → Nov 2019 | Wiskott-Aldrich syndrome | Genethon | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV-w1.6 WASp | “treatment of children with a state-of-the-art self-inactivating lentiviral vector (LV-w1.6 WASp) has resulted in significant clinical benefit without inducing selection of...” PMID 28716862 ↗ Jul 2017 |
| Route | Other | “transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene” NCT01347242 ↗ |
| Target | WAS | “lentiviral vector containing the human WAS gene” NCT01347242 ↗ |